Misoprostol

Limits on what this shows

• Null findings: Normal liver histology after 9 days of misoprostol in rats [10] (structure only, not a mitochondrial assay). No normoxic misoprostol-alone mitochondrial assay was found in the sources opened.
• At-risk subgroups: None identified.

Regulatory status

Not addressed in the label [1].

Population evidence

Cells and animals only (Tier B). PC12 cells: misoprostol significantly attenuated the MPP+-induced mitochondrial membrane permeability change, reduced pro-apoptotic proteins and caspase-3 activation, and protected against rotenone [11]. Hypoxia (48 hours, 10% O2) lowered mitochondrial membrane potential in the cell models used (HCT-116, H9c2 and primary neonatal myocytes were the systems listed), and 10 uM misoprostol completely attenuated this; in vivo dosing was 10 mcg/kg subcutaneously [12]. In neonatal mice and cardiomyocytes, hypoxia reduced basal, maximal and spare respiratory capacity and misoprostol abrogated this [13].

Mechanism

PKA-mediated repression of full-length Bnip3 and induction of pro-survival splice variants, which block ER-to-mitochondria calcium transfer and permeability transition [12]; PKA phosphorylation of Bnip3 at threonine-181 [13].

Counter-evidence held on record

Counter-evidence and confounding The conditions are rescue models, so the data show protection against injury, not behavior of healthy mitochondria. Findings were read through a summarizing fetch tool for [12] and [13]. Framing caution Reverse-direction, preclinical. It says nothing about human mitochondrial burden and is not a basis for any supplement recommendation.

Limits on what this shows

• Null findings: Misoprostol-alone groups showed no change in kidney markers [9] and no change in liver GSH or MDA [10].
• At-risk subgroups: None. Not a depletion finding.

Regulatory status

Not addressed in the label [1].

Population evidence

Rats, paclitaxel kidney model: 28 female Sprague Dawley rats, 4 groups of 7, misoprostol 0.2 mg/kg orally. Paclitaxel raised MDA, creatinine and BUN and lowered SOD, GSH and catalase; adding misoprostol reversed these; the misoprostol-alone group showed no significant difference from control [9]. Rats, liver: 24 male Sprague Dawley rats, misoprostol 100 mcg/kg twice daily for 9 days (tissue taken day 10), with or without celecoxib 40 mg/kg; liver GSH (ANOVA p=0.4878) and MDA showed no group difference and histology was normal [10]. Cells: in differentiated PC12 cells, misoprostol blocked MPP+-induced ROS formation and GSH depletion [11]. Hypoxia models: misoprostol prevented hypoxia-induced superoxide accumulation in cells [12] and in neonatal mouse heart [13].

Mechanism

Protective signaling through PKA and Bnip3 regulation is proposed in the hypoxia papers [12][13]; PC12 authors attribute protection to suppressed ROS formation and prevented GSH loss [11]. No pro-oxidant mechanism for misoprostol was found.

Counter-evidence held on record

Counter-evidence and confounding Doses are not human-equivalent, tissues are not the gut, and the protective models use toxins or hypoxia that have no counterpart in routine misoprostol use. Two additional rat studies of misoprostol with doxorubicin were seen as titles only and not opened. Framing caution Reverse-direction finding. It must not be presented as a benefit to consumers or as evidence that antioxidant supplements are needed or unnecessary.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C source located, and no circulating consumer claim about misoprostol and copper was found to rebut. Gap type: tooling-limited as well as possible genuine gap, because PubMed, PMC, OpenAlex search, Crossref search and further WebSearch were unavailable. Not a finding of safety. Kept independent of Iron (Hard Rule 7). Re-check when PubMed access is restored.

Channels tried

DailyMed Pfizer Cytotec label (no mineral mention) [1]. WebSearch "misoprostol iron absorption OR ferritin OR iron deficiency OR copper OR zinc serum levels": results were generic mineral pages, none naming misoprostol. Crossref bibliographic search "misoprostol copper OR zinc OR trace element": 429, not retried. Crossref iron query drifted to unrelated ferritin literature. OpenAlex search: 429. A WebSearch for nutrient-depletion lists naming misoprostol: no misoprostol entry; the Riordan Clinic handout [17] and a chiropractic-clinic PDF [18] were opened and do not mention misoprostol or prostaglandins. The Antidote Research misoprostol page URL returned 404. A final WebSearch hit its session cap (200 of 200).

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C iron evidence and no circulating iron claim for misoprostol. Hemoglobin outcomes are filed under Oxygen delivery/utilization as bleeding outcomes (Hard Rule 2: anemia is not iron deficiency). Gap type: tooling-limited as well as possible genuine gap. Not a finding of safety.

Channels tried

Label (no iron mention) [1]; the same WebSearch, Crossref and OpenAlex attempts listed under Copper; the PubMed listing of misoprostol with hemoglobin and postpartum hemorrhage (returned hemoglobin outcomes, no ferritin or iron-indices outcome) [8]; Sci Rep cohort [4] (hemoglobin fall only, no iron indices). Circulating-claim sources [17][18] do not mention misoprostol. The PubMed ferritin, iron and misoprostol search page itself was not retrieved (429).

Limits on what this shows

• Null findings: Horse diversity indices showed no treatment effect [15]. No dysbiosis or loss of commensals attributable to misoprostol was reported in either source.
• At-risk subgroups: None identified. Humans on antibiotics or with C. difficile are the setting of the mouse model and not a population in which misoprostol use was studied.

Regulatory status

No microbiome statement in the label sections retrieved [1].

Population evidence

Mouse C. difficile model: misoprostol protected against C. difficile-associated mortality, intestinal pathology and permeability, and promoted recovery of the gut microbiota after antibiotic perturbation; read from an abstract page via a summarizing fetch, with sample size and dose not captured [14]. Horses: 6 healthy geldings given 5 mcg/kg orally or rectally every 8 hours for 10 doses; Shannon and Simpson diversity did not differ (P over.05), community composition differed between treatments (P at or below.01), no taxa were identified at any level, and no diarrhea or change in fecal consistency was noted [15].

Mechanism

Named in the mouse paper only at the level of prostaglandins as host factors for recovery [14]. Whether diarrhea itself shifts stool microbiota in humans on misoprostol was not tested in any source opened.

Counter-evidence held on record

Counter-evidence and confounding Species and dose differences are large, the mouse result is a protective finding, and the horse composition difference is uninterpreted. Neither is evidence of microbiome harm in people. Framing caution This is not a claim of dysbiosis. Do not extend PPI or other acid-suppressor microbiome findings to misoprostol; they were not used here.

Limits on what this shows

• Null findings: The listing summary reports several PPH trials with no significant misoprostol-versus-comparator hemoglobin difference [8]; none of those individual trials were opened.
• At-risk subgroups: Not applicable as a drug-caused deficit. Patients with existing GI bleeding or heavy menstrual loss have anemia from those causes (Hard Rule 6).

Regulatory status

The label lists anemia, abnormal differential, thrombocytopenia, purpura and raised ESR under Blood/Coagulation adverse events; the frequency tier and any causality assessment were not captured in retrieval [1].

Population evidence

NSAID users: retrospective cohort, 9,133 osteoarthritis or rheumatoid arthritis patients on NSAIDs for 1 month or more, Samsung Medical Center 1995 to 2014. Occult GI bleeding was defined as a hemoglobin fall of at least 2 g/dL and occurred in 1,191 (13%) over a median 27 weeks. Misoprostol (named among the gastroprotective agents) had HR 0.47 (95% CI 0.23 to 0.95) versus non-users; misoprostol dose was not specified in the text retrieved [4]. Obstetric: a Tunisian placebo-controlled RCT of 400 mcg sublingual misoprostol (211 women) reported a smaller hemoglobin fall with misoprostol (1.21 vs 1.51 per 100 mL, p=0.02; wording and units come from a reconstructed OpenAlex abstract and are ambiguous) [5]. In 128 preeclamptic cesarean patients, the reconstructed abstract reports 24-hour hemoglobin of 10.39 and 9.53 with rectal and sublingual misoprostol versus 11.05 with oxytocin (lower with misoprostol, no baseline given), while a PubMed listing summary described the same trial as improved hemoglobin and hematocrit; the two summaries contradict each other and the trial is not used for direction [6][8]. A meta-analysis of tranexamic acid versus misoprostol for PPH was seen as metadata with a listing-level summary of no significant difference in hemoglobin change; its abstract was not opened [7][8]. A placebo-controlled RCT of misoprostol 200 mcg four times daily for 8 weeks in 84 aspirin users with small bowel bleeding found complete small bowel ulcer healing in 28.6% vs 9.5% (P=.026) [3]; one fetch returned a hemoglobin mean difference for this trial that was absent from the verbatim abstract on a second fetch, so no hemoglobin figure is used.

Mechanism

No mechanism for reduced oxygen delivery is named. Hemoglobin falls in the obstetric trials reflect blood loss, hemodilution and baseline maternal status. In NSAID users, a lower rate of hemoglobin fall is consistent with the drug's intended mucosal protection, which is a therapeutic effect, not a nutrient finding.

Counter-evidence held on record

Counter-evidence and confounding The cohort [4] is retrospective with confounding by indication; the authors note residual confounding from H. pylori and smoking and that menorrhagia was not excluded. Obstetric hemoglobin reflects delivery blood loss and the comparator (oxytocin or placebo), and the trials give no pre-treatment iron or hemoglobin status for a nutrient reading. Framing caution Anemia is not iron deficiency and a hemoglobin change is not an oxygen-delivery deficiency (Hard Rule 2). No nutrient claim is made. This entry is a context flag only.

Limits on what this shows

• Null findings: None located. No normoxic misoprostol-alone ATP data found.
• At-risk subgroups: None identified.

Regulatory status

Not addressed in the label [1].

Population evidence

Neonatal mouse hypoxia model (10% O2, postnatal days 3 to 10): cardiac ATP fell with hypoxia, and with misoprostol 10 mcg/kg subcutaneously "ATP levels were elevated beyond that observed in normoxic animals" (quoted from the summarizing fetch) [13]. Title taken from the search-result listing; authors and journal were not captured.

Mechanism

Preserved respiratory capacity and membrane potential through the PKA/Bnip3 axis [13]. Shared with the mitochondrial entry (see Overlap map).

Counter-evidence held on record

Counter-evidence and confounding Single source, animal model, neonatal heart under hypoxia, read through a summarizer. Not independent of the mitochondrial entry. Framing caution Not a claim about human energy levels. Kept independent of Mitochondrial burden and Oxygen delivery/utilization (Hard Rule 7).